{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:27:15Z","timestamp":1769088435295,"version":"3.49.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":3407,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T00:00:00Z","timestamp":1474416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gemcitabine is a commonly used antineoplastic agent used to treat a variety of cancers with rarely reported cardiac side effects. We describe a case of a 67-year-old woman with follicular lymphoma who experienced a rarely reported side effect of gemcitabine: cardiomyopathy. This case highlights a multiple hit mechanism of myocyte damage that may occur following the use of multiple cardio-toxic agents despite their administration in doses not associated with cardiotoxicity.<\/jats:p>","DOI":"10.1002\/ehf2.12113","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T04:53:02Z","timestamp":1474433582000},"page":"71-74","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Gemcitabine Induced Cardiomyopathy: A Case of Multiple Hit Cardiotoxicity"],"prefix":"10.1093","volume":"4","author":[{"given":"Donya","family":"Mohebali","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Matos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Ducksoon","family":"Chang","sequence":"additional","affiliation":[{"name":"Program in Cardio-oncology, Department of Internal Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,9,21]]},"reference":[{"key":"2026012115134793100_ehf212113-bib-0001","first-page":"3","article-title":"Gemcitabine: metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin Oncol"},{"key":"2026012115134793100_ehf212113-bib-0002","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/1752-1947-8-220","article-title":"Gemcitabine-induced cardiomyopathy: a case report and review of the literature","volume":"8","author":"Khan","year":"2014","journal-title":"J Med Case Rep"},{"key":"2026012115134793100_ehf212113-bib-0003","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","article-title":"Cardiotoxicity of anticancer treatments: what the cardiologist needs to know","volume":"7","author":"Ewe","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"2026012115134793100_ehf212113-bib-0004","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"key":"2026012115134793100_ehf212113-bib-0005","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenetics and Genomics"},{"key":"2026012115134793100_ehf212113-bib-0006","first-page":"8","article-title":"Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management","volume":"1","author":"Shakir","year":"2009","journal-title":"J Clin Med Res"},{"key":"2026012115134793100_ehf212113-bib-0007","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2001.19.1.191","article-title":"Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study","volume":"19","author":"Kremer","year":"2001","journal-title":"Journal of Clinical Oncology."},{"key":"2026012115134793100_ehf212113-bib-0008","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00001813-200603000-00016","article-title":"Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity","volume":"17","author":"Ferrari","year":"2006","journal-title":"Anti-Cancer Drugs"},{"key":"2026012115134793100_ehf212113-bib-0009","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1023\/A:1008380208045","article-title":"Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity","volume":"11","author":"Santini","year":"2000","journal-title":"Ann Oncol."},{"key":"2026012115134793100_ehf212113-bib-0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/000331970605700314","article-title":"Gemcitabine and acute myocardial infarction: a case report","volume":"57","author":"Bdair","year":"2006","journal-title":"Angiology"},{"key":"2026012115134793100_ehf212113-bib-0011","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/000331979905001208","article-title":"Acute myocardial infarction following gemcitabine therapy: a case report","volume":"50","author":"Kalapura","year":"1999","journal-title":"Angiology"},{"key":"2026012115134793100_ehf212113-bib-0012","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1517\/14740330802374262","article-title":"Gemcitabine: vascular toxicity and prothrombotic potential","volume":"7","author":"Dasanu","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"2026012115134793100_ehf212113-bib-0013","first-page":"2","article-title":"Preclinical, pharmacologic, and phase I studies of gemcitabine","volume":"24","author":"Storniolo","year":"1997","journal-title":"Semin Oncol"},{"key":"2026012115134793100_ehf212113-bib-0014","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clinical Lymphoma and Myeloma"},{"key":"2026012115134793100_ehf212113-bib-0015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1752-1947-8-252","article-title":"Cardiotoxicity following cyclophosphamide therapy: a case report","volume":"8","author":"Atalay","year":"2014","journal-title":"Journal of Medical Case Reports"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12113","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12113","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/4\/1\/71\/66225134\/eschf_4_1_71.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/4\/1\/71\/66225134\/eschf_4_1_71.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:18:43Z","timestamp":1769026723000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/4\/1\/71\/8413106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,21]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,21]]},"published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12113","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,2]]},"published":{"date-parts":[[2016,9,21]]},"assertion":[{"value":"2016-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}